This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Arthur Weinstein, MD; Danuta Bujak, RN, FNP; Abraham Mittelman, MD; Marianna Davidian, MD
New York Medical College Westchester Medical Center Valhalla

JAMA. 1987;258(21):3120-3121.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

To the Editor.—

Systemic administration of high-dose recombinant interleukin 2 (IL-2) and autologous lymphokineactivated killer (LAK) cells has been reported to be effective in the treatment of advanced cancer.¹ Toxic reactions are frequent and include fever, pruritus, rash, and myalgia.^1-3 We recently observed a patient with renal cell carcinoma who developed erythema nodosum (EN) after a course of IL-2/LAK cell therapy.

Report of a Case.—

A 26-year-old woman with an 18-month history of biopsy-proved renal cell carcinoma with lymphatic and lung involvement was referred for evaluation of a rash, arthralgia, and leg swelling of ten days' duration. Three weeks prior to this episode, she had been discharged from Westchester Medical Center, where she had received, for the second time, a three-week course of IL-2/LAK cell therapy for her metastatic disease.⁴ During that hospitalization, she had also received methadone, diazepam (Valium), Maalox, Demerol Compound, diphenhydramine hydrochloride (Benadryl), a . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?